|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Effectiveness of exercise in hepatic fat mobilization in nonalcoholic fatty liver disease: Systematic review显示文摘AIM: To investigate the efficacy of exercise interventions on hepatic fat mobilization in non-alcoholic fatty liver disease(NAFLD) patients.METHODS: Ovid-Medline, Pub Med, EMBASE and Cochrane database were searched for randomized trials and prospective cohort studies in adults aged ≥ 18 which investigated the effects of at least 8 wk of exercise only or combination with diet on NAFLD from 2010 to 2016. The search terms used to identify articles, in which exercise was clearly described by type, duration, intensity and frequency were: 'NASH', 'NAFLD', 'nonalcoholic steatohepatitis', 'non-alcoholic fatty liver disease', 'fat', 'steatosis', 'diet', 'exercise', 'MR spectroscopy' and 'liver biopsy'. NAFLD diagnosis, as well as the outcome measures, was confirmed by either hydrogen-magnetic resonance spectroscopy(H-MRS) or biopsy. Trials that included dietary interventions along with exercise were accepted if they met all criteria. RESULTS: Eight studies met selection criteria(6 with exercise only, 2 with diet and exercise with a total of 433 adult participants). Training interventions ranged between 8 and 48 wk in duration with a prescribed exercise frequency of 3 to 7 d per week, at intensities between 45% and 75% of VO2 peak. The most commonly used imaging modality was H-MRS and one study utilized biopsy. The effect of intervention on fat mobilization was 30.2% in the exercise only group and 49.8% in diet and exercise group. There was no difference between aerobic and resistance exercise intervention, although only one study compared thetwo interventions. The beneficial effects of exercise on intrahepatic triglyceride(IHTG) were seen even in the absence of significant weight loss. Although combining an exercise program with dietary interventions augmented the reduction in IHTG, as well as improved measures of glucose control and/or insulin sensitivity, exercise only significantly decreased hepatic lipid contents.CONCLUSION: Prescribed exercise in subjects with NAFLD reduces IHTG independent of dietary intervention. Diet and exercise was more effective than exercise alone in reducing IHTG. | Pegah Golabi Cameron T Locklear Patrick Austin Sophie Afdhal Melinda Byrns Lynn Gerber Zobair M Younossi | 2016 | World Journal of Gastroenterology2016，22，27： | 30 |
| 2 | Importance of fatigue and its measurement in chronic liver disease显示文摘The mechanisms of fatigue in the group of people with non-alcoholic fatty liver disease and non-alcoholic steatohepatitis are protean. The liver is central in the pathogenesis of fatigue because it uniquely regulates much of the storage, release and production of substrate for energy generation. It is exquisitely sensitive to the feedback controlling the uptake and release of these energy generation substrates. Metabolic contributors to fatigue, beginning with the uptake of substrate from the gut, the passage through the portal system to hepatic storage and release of energy to target organs (muscle and brain) are central to understanding fatigue in patients with chronic liver disease. Inflammation either causing or resulting from chronic liver disease contributes to fatigue, although inflammation has not been demonstrated to be causal. It is this unique combination of factors, the nexus of metabolic abnormality and the inflammatory burden of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis that creates pathways to different types of fatigue. Many use the terms central and peripheral fatigue. Central fatigue is characterized by a lack of self-motivation and can manifest both in physical and mental activities. Peripheral fatigue is classically manifested by neuromuscular dysfunction and muscle weakness. Therefore, the distinction is often seen as a difference between intention (central fatigue) versus ability (peripheral fatigue). New approaches to measuring fatigue include the use of objective measures as well as patient reported outcomes. These measures have improved the precision with which we are able to describe fatigue. The measures of fatigue severity and its impact on usual daily routines in this population have also been improved, and they are more generally accepted as reliable and sensitive. Several approaches to evaluating fatigue and developing endpoints for treatment have relied of biosignatures associated with fatigue. These have been used singly or in combination and include: physical performance measures, cognitive performance measures, mood/behavioral measures, brain imaging and serological measures. Treatment with non-pharmacological agents have been shown to be effective in symptom reduction, whereas pharmacological agents have not been shown effective. | Lynn H Gerber Ali A Weinstein Rohini Mehta Zobair M Younossi | 2019 | World Journal of Gastroenterology2019，25，28： | 7 |
| 3 | The diagnosis and management of non‐alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association显示文摘 | Naga Chalasani Zobair Younossi Joel E. Lavine Anna Mae Diehl Elizabeth M. Brunt Kenneth Cusi Michael Charlton Arun J. Sanyal | 2012 | Hepatology2012，，6： | 5 |
| 4 | Changes in the Prevalence of the Most Common Causes of Chronic Liver Diseases in the United States From 1988 to 2008显示文摘 | Zobair M. Younossi Maria Stepanova Mariam Afendy Yun Fang Youssef Younossi Hesham Mir Manirath Srishord | 2011 | Clinical Gastroenterology and Hepatology2011，，6： | 5 |
| 5 | Predictors of All-Cause Mortality and Liver-Related Mortality in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)显示文摘 | Maria Stepanova Nila Rafiq Hala Makhlouf Ritambhara Agrawal Ishmeet Kaur Zahra Younoszai Arthur McCullough Zachary Goodman Zobair M. Younossi | 2013 | Digestive Diseases and Sciences2013，，10： | 4 |
| 6 | Nonalcoholic Steatohepatitis is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the U.S.显示文摘 | Robert J. Wong Maria Aguilar Ramsey Cheung Ryan B. Perumpail Stephen A. Harrison Zobair M. Younossi Aijaz Ahmed | 2014 | Gastroenterology2014，，： | 3 |
| 7 | Long-Term Follow-Up of Patients With Nonalcoholic Fatty Liver显示文摘 | Nila Rafiq Chunhong Bai Yun Fang Manirath Srishord Arthur McCullough Terry Gramlich Zobair M. Younossi | 2009 | Clinical Gastroenterology and Hepatology2009，，2： | 3 |
| 8 | Advances in cirrhosis: Optimizing the management of hepatic encephalopathy显示文摘Hepatic encephalopathy(HE) is a major complication of cirrhosis resulting in significant socioeconomic burden, morbidity, and mortality. HE can be further subdivided into covert HE(CHE) and overt HE(OHE). CHE is a subclinical, less severe manifestation of HE and requires psychometric testing for diagnosis. Due to the time consuming screening process and lack of standardized diagnostic criteria, CHE is frequently underdiagnosed despite its recognized role as a precursor to OHE. Screening for CHE with the availability of the Stroop test has provided a pragmatic method to promptly diagnose CHE. Management of acute OHE involves institution of lactulose, the preferred first-line therapy. In addition, prompt recognition and treatment of precipitating factors is critical as it may result in complete resolution of acute episodes of OHE. Treatment goals include improvement of daily functioning, evaluation for liver transplantation, and prevention of OHE recurrence. For secondary prophylaxis, intolerance to indefinite lactulose therapy may lead to non-adherence and has been identified as a precipitating factor for recurrent OHE. Rifaximin is an effective add-on therapy to lactulose for treatment and prevention of recurrent OHE. Recent studies have demonstrated comparable efficacy of probiotic therapy to lactulose use in both primary prophylaxis and secondary prophylaxis. | Andy Liu Ryan B Perumpail Radhika Kumari Zobair M Younossi Robert J Wong Aijaz Ahmed | 2015 | World Journal of Hepatology2015，7，29： | 3 |
| 9 | Independent Association Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease in the US Population显示文摘 | Maria Stepanova Zobair M. Younossi | 2012 | Clinical Gastroenterology and Hepatology2012，，6： | 3 |
| 10 | Epidemiology and Natural History of NAFLD and NASH显示文摘 | Janus P. Ong Zobair M. Younossi | 2007 | Clinics in Liver Disease2007，，1： | 3 |
| 11 | Nonalcoholic fatty liver disease: An agenda for clinical research显示文摘 | Zobair M. Younossi Anna Mae Diehl Janus P. Ong | 2002 | Hepatology2002，，： | 2 |
| 12 | Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity显示文摘 | Christi A. Matteoni * Zobair M. Younossi * Terry Gramlich ? Navdeep Boparai § Yao Chang Liu ∥ Arthur J. McCullough ? | 1999 | Gastroenterology1999，，6： | 2 |
| 13 | Manifestations of Chronic Hepatitis C Virus Infection Beyond the Liver显示文摘 | Ira M. Jacobson Patrice Cacoub Luigino Dal Maso Stephen A. Harrison Zobair M. Younossi | 2010 | Clinical Gastroenterology and Hepatology2010，，12： | 2 |
| 14 | Long-Term Follow-Up of Patients With Nonalcoholic Fatty Liver显示文摘 | Nila Rafiq Chunhong Bai Yun Fang Manirath Srishord Arthur McCullough Terry Gramlich Zobair M. Younossi | 2009 | Clinical Gastroenterology and Hepatology2009，，2： | 2 |
| 15 | Changes in the Prevalence of the Most Common Causes of Chronic Liver Diseases in the United States From 1988 to 2008显示文摘 | Zobair M. Younossi Maria Stepanova Mariam Afendy Yun Fang Youssef Younossi Hesham Mir Manirath Srishord | 2011 | Clinical Gastroenterology and Hepatology2011，，6： | 2 |
| 16 | Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure显示文摘 | Stanislas Pol Jeroen Aerssens Stefan Zeuzem Pietro Andreone Eric J. Lawitz Stuart Roberts Zobair Younossi Graham R. Foster Roberto Focaccia Andrzej Horban Paul J. Pockros Rolf P.G. Van Heeswijk Sandra De Meyer Don Luo Martyn Botfield Maria Beumont Gaston | 2013 | Journal of Hepatology2013，，5： | 2 |
| 17 | Ultrasound-Guided Liver Biopsy for Parenchymal Liver Disease (An Economic Analysis)显示文摘 | Zobair M. Younossi J. Carlos Teran Theodore G. Ganiats William D. Carey | 1998 | Digestive Diseases and Sciences1998，，1： | 2 |
| 18 | Long-Term Follow-Up of Patients With Nonalcoholic Fatty Liver显示文摘 | Nila Rafiq Chunhong Bai Yun Fang Manirath Srishord Arthur McCullough Terry Gramlich Zobair M. Younossi | 2009 | Clinical Gastroenterology and Hepatology2009，，2： | 1 |
| 19 | Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure显示文摘 | Stanislas Pol Jeroen Aerssens Stefan Zeuzem Pietro Andreone Eric J. Lawitz Stuart Roberts Zobair Younossi Graham R. Foster Roberto Focaccia Andrzej Horban Paul J. Pockros Rolf P.G. Van Heeswijk Sandra De Meyer Don Luo Martyn Botfield Maria Beumont Gaston | 2013 | Journal of Hepatology2013，，5： | 1 |
| 20 | Expression of Cytokine Signaling Genes in Morbidly Obese Patients with Non-Alcoholic Steatohepatitis and Hepatic Fibrosis显示文摘 | J. Michael Estep Ancha Baranova Noreen Hossain Hazem Elariny Kathy Ankrah Arian Afendy Vikas Chandhoke Zobair M. Younossi | 2009 | Obesity Surgery2009，，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员